[HTML][HTML] Evaluation of Apixaban safety and effectiveness in morbidly obese patients with atrial fibrillation: a retrospective cohort study

K Al Sulaiman, HA Badreldin, GB Korayem… - Thrombosis …, 2022 - Springer
Background The benefit of apixaban to reduce stroke risk in morbidly obese patients with
nonvalvular atrial fibrillation (AF) is still undetermined. The International Society of …

[HTML][HTML] Evaluation of Apixaban safety and effectiveness in morbidly obese patients with atrial fibrillation: a retrospective cohort study

K Al Sulaiman, HA Badreldin, GB Korayem… - Thrombosis …, 2022 - ncbi.nlm.nih.gov
Background The benefit of apixaban to reduce stroke risk in morbidly obese patients with
nonvalvular atrial fibrillation (AF) is still undetermined. The International Society of …

Evaluation of Apixaban safety and effectiveness in morbidly obese patients with atrial fibrillation: a retrospective cohort study.

K Al Sulaiman, HA Badreldin, GB Korayem… - Thrombosis …, 2022 - europepmc.org
Background The benefit of apixaban to reduce stroke risk in morbidly obese patients with
nonvalvular atrial fibrillation (AF) is still undetermined. The International Society of …

Evaluation of Apixaban safety and effectiveness in morbidly obese patients with atrial fibrillation: a retrospective cohort study.

K Al Sulaiman, HA Badreldin, GB Korayem… - Thrombosis …, 2022 - search.ebscohost.com
Background: The benefit of apixaban to reduce stroke risk in morbidly obese patients with
nonvalvular atrial fibrillation (AF) is still undetermined. The International Society of …

Evaluation of Apixaban safety and effectiveness in morbidly obese patients with atrial fibrillation: a retrospective cohort study

K Al Sulaiman, HA Badreldin, GB Korayem… - Thrombosis …, 2022 - search.proquest.com
Background The benefit of apixaban to reduce stroke risk in morbidly obese patients with
nonvalvular atrial fibrillation (AF) is still undetermined. The International Society of …

Evaluation of Apixaban safety and effectiveness in morbidly obese patients with atrial fibrillation: a retrospective cohort study

K Al Sulaiman, HA Badreldin… - Thrombosis …, 2022 - pubmed.ncbi.nlm.nih.gov
Background The benefit of apixaban to reduce stroke risk in morbidly obese patients with
nonvalvular atrial fibrillation (AF) is still undetermined. The International Society of …

[HTML][HTML] Evaluation of Apixaban safety and effectiveness in morbidly obese patients with atrial fibrillation: a retrospective cohort study

K Al Sulaiman, HA Badreldin… - Thrombosis …, 2022 - thrombosisjournal.biomedcentral …
The benefit of apixaban to reduce stroke risk in morbidly obese patients with nonvalvular
atrial fibrillation (AF) is still undetermined. The International Society of Thrombosis and …

[PDF][PDF] Evaluation of Apixaban safety and effectiveness in morbidly obese patients with atrial fibrillation: a retrospective cohort study

K Al Sulaiman, HA Badreldin, GB Korayem, AA Alenazi… - 2022 - researchgate.net
Background: The benefit of apixaban to reduce stroke risk in morbidly obese patients with
nonvalvular atrial fibrillation (AF) is still undetermined. The International Society of …

[PDF][PDF] Evaluation of Apixaban safety and effectiveness in morbidly obese patients with atrial fibrillation: a retrospective cohort study

K Al Sulaiman, HA Badreldin, GB Korayem… - 2022 - thrombosisjournal.biomedcentral …
Background: The benefit of apixaban to reduce stroke risk in morbidly obese patients with
nonvalvular atrial fibrillation (AF) is still undetermined. The International Society of …